On the 3rd of June Joint-stock company Grindeks celebrates Ridgepole celebrations of the new waste water purification plant building, thus expressing support to the World Environment Day whose theme this year is Green Cities. The Purification plant is being constructed, in order to prevent efficiently the possible harm to the environment.

Construction of the purification plant is one of the most significant development projects of the company in 2008. Construction was started in September, 2007, and it is planned to be finished by the end of2008. The total investments for implementation of the project will be almost 2.5 million lats.

Chairman of the Council of JSC Grindeks Kirovs Lipmans stresses: „The rapid growth of Grindeks allows investing of increasingly greater means in development and improvement of production infrastructure. Construction of technologically modern purification plant is a purposefully planned investment project, in order that we, increasing production capacities, could ensure not only a stable increase of Grindeks’ turnover, but also to care efficiently for environment protection.”

Chairman of the Board of JSC Grindeks Jānis Romanovskis emphasizes the responsibility of the company in front of environment and society: „We are aware that we are working in Riga city, and our responsibility is to engage actively in conservation of city environment, ensuring environmentally friendly production processes. Grindeks is a „green thinking” company – all our technological processes and development projects, among them the new waste water purification plant, are directed to maximal conservation and non-pollution of environment.”

The technological project of purification plant is being developed by Swedish company Anox Kaldnes which has an important experience of implementation of specific pharmacy sewage purification projects for other big pharmaceutical companies. Construction work is carried out by Latvian construction company Ekotehnoloģijas.

Overview of JSC Grindeks

JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of Grindeks products covers a successful combination of original products and generics. It includes the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics.

The holding company of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia. It has representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of Riga Stock Exchange.

You are kindly invited to www.grindeks.lv to get to know more about our company!

Laila Kļaviņa,
JSC Grindeks
Head of Department of communications
E-mail: laila.klavina@grindeks.lv
Phone: 67083370, 29256012